Read here for an update on key Q1 2025 portfolio moves by Duquesne Family Office. Get insights into top holdings, new ...

Eli Lilly and Company (NYSE:LLY) is a leading medicine company which discovers, develops, manufactures, and markets products ...

It plans to submit orforglipron for FDA approval for obesity in Q4, and for type 2 diabetes ... On the day of Eli Lilly's earnings report, CVS Health announced that its pharmacy benefit manager ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE ... of hedge funds that have stakes in them, as of Q4 2024, which was sourced from Insider Monkey’s database.

Hims & Hers has delivered strong results and partnerships, but recent Cigna/Novo Nordisk news increases competitive risk and ...

Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker ... It plans to submit orforglipron for FDA approval for obesity in Q4, and for type 2 diabetes in the first half of 2026.

Looking ahead, Wall Street forecasts adjusted EPS of $23.21 for fiscal 2025, representing a 78.7% increase from $12.99 in ...

Amid concerns over trade restrictions and a weakening economy, some investors are seeking stability in dividend-paying stocks ...

Eli Lilly’s remarkable revenue growth was primarily volume-driven, ... The company plans to submit regulatory applications for obesity in Q4 2025 and for type 2 diabetes in the first half of 2026.

Best Pharma Stocks to Invest in Now. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) ...